Summary
The sodium glucose cotransporter 2 inhibitor canagliflozin is associated with durable glycemic improvement over 104 weeks compared with glimepiride in patients with type 2 diabetes mellitus (T2DM) on background metformin therapy. Such was the primary finding of a Phase 3 randomized, double-blind efficacy and safety study.
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- Diabetes Mellitus
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- Endocrinology
- Diabetes & Metabolic Syndrome
- Diabetes Mellitus
- © 2013 MD Conference Express®
Tools
Glycemic Improvement with Canagliflozin is Durable in T2DM Patients on Metformin
Permalink:
Table of contents
Cited By...
- No citing articles found.